Comparative Pharmacology
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 IN DEXTROSE 25 IN PLASTIC CONTAINER.
EPANOVA vs TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Travasol 2.75% in Dextrose 25% is a parenteral nutrition solution providing amino acids and carbohydrates. The amino acids serve as substrates for protein synthesis, while dextrose provides a source of calories and spares protein catabolism. It does not have a direct pharmacological target but supports metabolic functions.
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous administration only. Typical adult dose is 1 to 2 L per day, infused at a rate of 100 to 200 mL per hour, adjusted based on metabolic and fluid needs. Contains 2.75% amino acids and 25% dextrose.
None Documented
None Documented
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Not applicable as a single entity; amino acids have variable half-lives (minutes to hours), dextrose has a half-life of 1.5-2 hours in normoglycemic patients; clinical context: continuous infusion maintains steady state.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Renal: 100% as amino acids and dextrose metabolites; negligible biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution